Next Generation Sequencing (NGS) Market Is Estimated To Reach Around $21.4 Billion By 2025: Grand View Research, Inc.

The global next generation sequencing market is anticipated to reach USD 21.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing coverage of NGS is expected to drive use of precision medicine in oncology from research based setting to clinical cancer setting. Commercial payers are also engaged in reviewing the existing and novel tests in order to establish appropriate medical necessity criteria for their clinical and medical policies.

Moreover, improved understanding of the genetic markers of virulence and resistance provided by next generation sequencing is expected to drive demand of the technology in infectious disease diagnosis.

To request a sample copy or view summary of this report:
www.grandviewresearch.com/industry-analysis/next-generation-sequencing-market

UK NGS market revenue, by technology, 2013 – 2024 (USD Million)

Further key findings from the study suggest:

  • Oncology accounted for the dominant share owing to phase-resolved and unambiguous results obtained by using single assay systems, and analysis program.
  • Targeted resequencing dominated the market owing to its associated benefits such as implementation of the technique such as lower turnaround time and more manageable data sets.
  • Academic usage of NGS accounted for the largest share with respect to market revenue by end uses and is anticipated to maintain its dominance.
  • Higher adoption of this technology and platforms in university projects is expected to support the estimated share.
  • Asia Pacific is estimated to witness the fastest growth over the forecast period owing to expected routing of a considerable portion of whole genome sequencing requirements herein.
  • Key players operating in the NGS market include Illumina Inc., Agilent Technologies, BGI, Pacific Biosciences, Qiagen, Roche, Thermo Fischer Scientific, and Oxford Nanopore Technologies Ltd.
  • Endeavors adopted by participants are such as acquisition of Enzymatics by Qiagen acquired solutions in order to enhance the product portfolio with respect to reagents needed in preparatory steps.

Related Report of Biotechnology:

Grand View Research has segmented the NGS market on the basis of application, technology, workflow, and end use:

NGS Outlook, by Application (Revenue, USD Million; 2014 – 2025)

  • Reproductive Health
    • NIPT
    • PGT
    • Newborn/Genetic Screening
  • Oncology
  • HLA Typing/Immune System Monitoring
  • Metagenomics, Epidemiology & Drug Development
  • Agrigenomics & Forensics
  • Consumer Genomics
  • Clinical Investigation
    • Idiopathic Diseases
    • Inherited Diseases
    • Infectious Diseases
    • Non-Communicable / Other Diseases

NGS Outlook, by Technology (Revenue, USD Million; 2014 – 2025)

  • Targeted Sequencing Analysis
    • DNA Based Targeted Sequencing Analysis
    • RNA Based Targeted Sequencing Analysis
  • Whole Genome Sequencing
  • Whole Exome Sequencing

NGS Outlook, by Workflow (Revenue, USD Million; 2014 – 2025)

  • Pre-sequencing
    • NGS Library Preparation Kits
    • NGS Semi-automated Library Preparation
    • NGS Automated Library Preparation
    • Clonal Amplification
  • Sequencing
    • Data Analysis
      • Primary Data Analysis
      • Secondary Data Analysis
      • Tertiary Data Analysis

NGS Outlook, by End-use (Revenue, USD Million; 2014 – 2025)

  • Academic Research
  • Clinical Research
  • Hospitals & Clinics
  • Pharma & Biotech Entities
  • Other Users

NGS Outlook, by Region (Revenue, USD Million; 2014 – 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
  • Middle East & Africa
    • South Africa

Access Press Release Of This Research Report by Grand View Research: www.grandviewresearch.com/press-release/global-next-generation-sequencing-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058

Toll Free: 1-888-202-9519

Email: sales@grandviewresearch.com

For More Info: www.grandviewresearch.com

Matched content

Editor’s pick